Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy
Authors:
- 2 March 2022
- journal article
- research article
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 36 (2) , 907-917
Abstract
Background/Aim: The inflammation-based prognostic score (IBPS) has attracted attention recently as a prognostic biomarker for head and neck cancer patients. However, as the IBPS often changes after anticancer drug therapy, its independent prognostic value remains controversial. We aimed to investigate the relationship between the IBPS and prognosis in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with nivolumab, and investigate changes in the IBPS before and after nivolumab treatment. Patients and Methods: Total of 164 patients with RMHNSCC received nivolumab therapy were retrospectively analyzed. Results: Univariate analysis among the 164 patients revealed that the performance status (PS), immune-related adverse event (irAE) status, pre- and post-therapy Glasgow Prognostic Score (GPS), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), platelet-to-lymphocyte ratio (PLR), and post-eosinophil count, were all significant predictors of overall survival (OS) (p<0.05). A multivariate analysis revealed that PS, irAEs, post-GPS, post-NLR, post-CAR, and post-eosinophil count were independent prognostic factors for overall survival. Conclusion: Post-treatment factors were identified as independent prognostic factors for RMHNSCC and can more accurately predict prognosis compared to nivolumab-treated RMHNSCC pre-treatment factors.Keywords
This publication has 43 references indexed in Scilit:
- Towards a simple objective framework for the investigation and treatment of cancer cachexia: The Glasgow Prognostic ScoreCancer Treatment Reviews, 2014
- Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinomaHead & Neck, 2013
- Correlation Between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Advanced Esophageal CancerWorld Journal of Surgery, 2012
- Acute‐phase response reactants as objective biomarkers of radiation‐induced mucositis in head and neck cancerHead & Neck, 2011
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysisBritish Journal of Cancer, 2011
- Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancerBiomarkers, 2010
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Comparison of an inflammation‐based prognostic score (GPS) with performance status (ECOG‐ps) in patients receiving palliative chemotherapy for gastroesophageal cancerJournal of Gastroenterology and Hepatology, 2008
- Activated human neutrophils release hepatocyte growth factor/scatter factorEuropean Journal of Surgical Oncology, 2001
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001